HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the appointment of Steve Schoch as chief financial officer (CFO) and the promotion of Phil Aulson ...

RefleXion Medical’s SCINTIX biology-guided radiotherapy platform (BgRT) has shined in an observational study involving lung and bone cancer patients. During the US-based PREMIER trial (NCT05406167), ...

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality that will one day treat all stages of cancer, ...

Just over a year after being recognized by the FDA for the potential “breakthrough” nature of its radiation therapy technology, RefleXion Medical has gotten the go-ahead from the agency to begin ...

After winning an FDA clearance earlier this year for its image-guided radiation treatment for cancer, RefleXion Medical has raised $105 million to boost commercialization efforts as well as develop ...

RefleXion Medical, an external-beam theranostic oncology company, today announced that two Medicare Administrator Contractors (MACs) have established payment rates for SCINTIX® autonomous radiotherapy ...

What if you could take cancer’s natural activity in the human body and turn it back on itself? That’s the premise behind RefleXion, which made its debut at last week’s ASTRO Annual Meeting with a ...

RefleXion Medical announces the promotion of Phil Aulson to chief operating officer. The theranostic oncology company develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking ...